The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib

Abstract Lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), effectively targets most single ALK mutations in ALK-positive non-small cell lung cancer (NSCLC), while acquired resistance remains a major clinical challenge. In this study, we identified a novel ALK K1150dup mutation in a...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Mai Nagasaka, Francesco Facchinetti, Ludovic Bigot, Floriane Brayé, Matthew R. Groves, Juvenal Yosa, Anthonie van der Wekken, Mihaela Aldea, Benjamin Besse, David Planchard, Charles Naltet, Ryohei Katayama, Ken André Olaussen, Yohann Loriot, Luc Friboulet
Format:	Artigo
Sprog:	Inglês
Udgivet:	Nature Portfolio 2026-05-01
Serier:	npj Precision Oncology
Online adgang:	https://doi.org/10.1038/s41698-026-01477-z
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!